[1]Jeffries MA. Osteoarthritis year in review 2018: genetics and epigenetics. Osteoarthritis Cartilage, 2019, 27: 371–377 DOI: 10.1016/j.joca.2018.10.004.
[2]Simon TC, Jeffries MA. The Epigenomic Landscape in Osteoarthritis. Curr Rheumatol Rep, 2017, 19: 30 DOI: 10.1007/s11926–017–0661–9.
[3]Kerkhof HJ, Doherty M, Arden NK, et al. Large-scale meta-analysis of interleukin–1 beta and interleukin–1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritis. Osteoarthritis Cartilage, 2011, 19: 265–271 DOI: 10.1016/j.joca.2010.12.003.
[4]van Dalen SC, Blom AB, Sloetjes AW, et al. Interleukin–1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. Osteoarthritis Cartilage, 2017, 25: 385–396 DOI: 10.1016/j.joca.2016.09.009.
[5]Xu X, Liu X, Yang Y, et al. Resveratrol inhibits the development of obesity-related osteoarthritis via the TLR4 and PI3K/Akt signaling pathways. Connect Tissue Res, 2019: 1–12 DOI: 10.1080/03008207.2019.1601187.
[6]Wei Y, Jia J, Jin X, et al. Resveratrol ameliorates inflammatory damage and protects against osteoarthritis in a rat model of osteoarthritis. Mol Med Rep, 2018, 17: 1493–1498 DOI: 10.3892/mmr.2017.8036.
[7]Saito T, Tanaka S. Molecular mechanisms underlying osteoarthritis development: Notch and NF-kappaB. Arthritis Res Ther, 2017, 19: 94 DOI: 10.1186/s13075–017–1296-y.
[8]Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 2004, 24: 2783–2840
[9]Hussain SA, Marouf BH, Ali ZS, et al. Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study. Clin Interv Aging, 2018, 13: 1621–1630 DOI: 10.2147/cia.s172758.
[10]Kang DG, Lee HJ, Lee CJ, et al. Inhibition of the Expression of Matrix Metalloproteinases in Articular Chondrocytes by Resveratrol through Affecting Nuclear Factor-Kappa B Signaling Pathway. Biomol Ther (Seoul), 2018, 26: 560–567 DOI: 10.4062/biomolther.2018.132.
[11]Aida Y, Maeno M, Suzuki N, et al. The effect of IL–1beta on the expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human chondrocytes. Life Sci, 2005, 77: 3210–3221 DOI: 10.1016/j.lfs.2005.05.052.
[12]Wiegertjes R, van Caam A, van Beuningen H, et al. TGF-beta dampens IL–6 signaling in articular chondrocytes by decreasing IL–6 receptor expression. Osteoarthritis Cartilage, 2019: DOI: 10.1016/j.joca.2019.04.014.
[13]Tang J, Dong Q. Knockdown of TREM–1 suppresses IL–1beta-induced chondrocyte injury via inhibiting the NF-kappaB pathway. Biochem Biophys Res Commun, 2017, 482: 1240–1245 DOI: 10.1016/j.bbrc.2016.12.019.
[14]Gu H, Jiao Y, Yu X, et al. Resveratrol inhibits the IL–1beta-induced expression of MMP–13 and IL–6 in human articular chondrocytes via TLR4/MyD88-dependent and -independent signaling cascades. Int J Mol Med, 2017, 39: 734–740 DOI: 10.3892/ijmm.2017.2885.
[15]Rigoglou S, Papavassiliou AG. The NF-kappaB signalling pathway in osteoarthritis. Int J Biochem Cell Biol, 2013, 45: 2580–2584 DOI: 10.1016/j.biocel.2013.08.018.
[16]Ulivi V, Giannoni P, Gentili C, et al. p38/NF-kB-dependent expression of COX–2 during differentiation and inflammatory response of chondrocytes. J Cell Biochem, 2008, 104: 1393–1406 DOI: 10.1002/jcb.21717.
[17]Cheleschi S, Fioravanti A, De Palma A, et al. Methylsulfonylmethane and mobilee prevent negative effect of IL–1beta in human chondrocyte cultures via NF-kappaB signaling pathway. Int Immunopharmacol, 2018, 65: 129–139 DOI: 10.1016/j.intimp.2018.10.004.
[18]Wang Y, Chen Y, Chen Y, et al. Eriodictyol inhibits IL–1beta-induced inflammatory response in human osteoarthritis chondrocytes. Biomed Pharmacother, 2018, 107: 1128–1134 DOI: 10.1016/j.biopha.2018.08.103.